Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer.

作者：Mitchell Parma, Eric K. Singhi, Luisa M. Solis, Wei‐Lien Wang, Mehmet Altan, Maria Franco-Vega, Alexa Halliday, João Gomes Jácome, Jianjun Zhang, John V. Heymach, Lauren A. Byers, Carl M. Gay, Bingnan Zhang · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco.2025.43.16_suppl.8088 · 被引用次数：5 · 研究领域：Lung Cancer Research Studies、Peptidase Inhibition and Analysis、Cancer therapeutics and mechanisms

8088 Background: Tarlatamab, a bispecific T cell engager targeting Delta-Like ligand 3, received FDA approval in May 2024 for patients with relapsed extensive-stage small cell lung cancer (SCLC). While the clinical trials leading to its approval demonstrated impressive objective response, it has unique toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Here, we report a real-world case series of safety and efficacy data for patients treated with standard of care tarlatamab at MD Anderson Cancer Center. Methods: We queried the MD Anderson Lung Cancer GEMINI database for patients treated with tarlatamab and retrospectively collected demographic, clinical, and outcome data. From 7/1/2024-1/15/2025, a total of 39 patients received tarlatamab. 8 patients were excluded from analysis either due to diagnosis of extrapulmonary small cell cancer or rapid clinical deterioration due to disease progression around the time of the first tarlatamab infusion. The final cohort consisted of 31 patients. Results: The average age of our cohort was 66 years, 36% of patients were of non-white race, and their median lines of prior treatment was 2. 4 patients had transformed SCLC from classical EGFR-mutant lung adenocarcinoma (EGFR transformed), and 12 patients had untreated brain metastases (BM) prior to tarlatamab initiation. Safety data is summarized in the Table. At the cutoff, 17 patients had their first repeat systemic imagin...